CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: It has been shown that Dasatinib inhibits the STAT3 and STAT5 signaling pathways through the inhibition of Src kinases, leading to a durable inhibition of STAT5 phosphorylation, but only a transient inhibition of STAT3 phosphorylation in CD34+ cells isolated from CML patients at diagnosis (39).